GuidelineHepatology international2025
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.
Guideline in Hepatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.Hepatology international · 2026Guideline
- Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.Journal of gastroenterology · 2026Guideline
- Comparative efficacy of drugs with different mechanistic pathways/targets in the treatment of pediatric NAFLD: evidence from a Bayesian network meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study.Frontiers in nutrition · 2025Pooled it
- Effect of Essential Phospholipids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Phase 4 Clinical Trial.Liver international : official journal of the International Association for the Study of the Liver · 2026Trial
- Therapeutic Effects of a WeChat Mini-Program on Metabolic Dysfunction-Associated Fatty Liver Disease: Randomized Controlled Trial.Journal of medical Internet research · 2026Trial
- Pistacia atlantica can improve oxidative status in patients with metabolic dysfunction-associated fatty liver disease.Scientific reports · 2025Trial
- Plasma proteome profiling identifies XPNPEP3 as a novel biomarker associated with metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus.Annals of medicine · 2026Article
- Metabolic Dysfunction-Associated Fatty Liver Disease-Cardiovascular-Kidney-Metabolic (MAFLD-CKM): A Modified Framework to Predict Long-Term Mortality.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Hydroxysafflor yellow A attenuates microcirculatory disturbance in MAFLD via the EGFR/MAPK1 pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Converging pathways: the interaction between estimated glucose disposal rate and atherogenic index of plasma in MASLD risk stratification.Hepatology international · 2026Article
- Inhibition of Acetylation Activity of p300/CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Identifying MASLD Patients with MASH or Significant Fibrosis: The Role of Lower ALT Thresholds.Journal of clinical medicine · 2026Article
- How to apply artificial intelligence (AI) to facilitate and enhance MASH trials.Hepatology international · 2026Review
- Outcome of Targeted Therapy for Obstructive Sleep Apnea in Children with Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Children (Basel, Switzerland) · 2026Article
- Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.Nature reviews. Gastroenterology & hepatology · 2026Review
- Predictive modeling and clinical decision tools for risk stratification in steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- MRI in MASLD: technical foundations and guideline-based applications.BMJ open gastroenterology · 2026Review
- MRI-Derived Evaluation of Liver Function and Its Extension to K-Edge Photon-Counting CT: Focus on Gadolinium-Based Functional Biliary Imaging.Diagnostics (Basel, Switzerland) · 2026Review
76 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
59 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association for the Study of the Liver (APASL) has created clinical practice guidelines focused on MAFLD. The guidelines cover various aspects of the disease, such as its epidemiology, diagnosis, screening, assessment, and treatment. The guidelines aim to advance clinical practice, knowledge, and research on MAFLD, particularly in special groups. The guidelines are designed to advance clinical practice, to provide evidence-based recommendations to assist healthcare stakeholders in decision-making and to improve patient care and disease awareness. The guidelines take into account the burden of clinical management for the healthcare sector.
Indexed as
Identifiers
40016576What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.